Highlight moment!

It's eye-catching and ready to go
.

The 2021 American Society of Clinical Oncology (ASCO) annual meeting will be held online from June 4 to June 8.

As a pioneer and leader in the development of innovative drugs in China, Hengrui Pharmaceuticals will bring a number of research and development drugs to the ASCO annual meeting this year.
The treatment areas cover breast cancer, gastrointestinal tumors, liver cancer, lung cancer, head and neck tumors and other fields
.

Among them, the "Shuang Ai combination" (carrelizumab combined with apatinib) ushered in a bright moment, and a total of 14 studies were selected for the poster and abstract section of this conference

In April this year, 2 sets of CCTV's "Economy Half an Hour" column praised Hengrui Medicine Carrelizumab (Erica®️) and Hengrui independently developed another innovative drug, apatinib (Aitan®️).
The "Double Ai" program of China is called the "new nemesis" of persistent liver cancer diseases
.

The "Double Ai" program has made breakthrough progress in the treatment of advanced liver cancer in recent years
.

The results of the RESCUE study published in the journal "Clinical Cancer Research" in 2020 showed that the ORR (objective effective rate) of the first-line treatment group of the "Double Ai" regimen was as high as 46%, the TTR (time to onset) was only 1.

From a mechanism point of view, apatinib is a VEGFR-2 inhibitor, and the combination with carrelizumab, the PD-1 monoclonal antibody, can fundamentally change the immune microenvironment, thereby strengthening the PD-1 monoclonal antibody The effect of "1+1>2"
.

The combination of immunotherapy and anti-angiogenesis targeted drugs has gradually become the standard treatment for advanced liver cancer
.

In 2020, the "Chinese Society of Clinical Oncology (CSCO) Liver Cancer Diagnosis and Treatment Guidelines" listed the "Shuang Ai" program as the first-line standard treatment program for advanced liver cancer

Hepatobiliary tumors: progress in multi-line treatment and more in-depth exploration

At this ASCO annual meeting, "Shuang Ai Combination" has a total of 5 studies in the field of liver cancer for data announcement and result update
.

Among them, the RESCUE study of carrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma led by Professor Jianming Xu updated the overall survival (OS) results.

In terms of perioperative treatment, a prospective, phase II study evaluating the efficacy and safety of carrelizumab combined with apatinib in the perioperative treatment of hepatocellular carcinoma was selected for the poster presentation of this conference.
Of the 17 patients undergoing surgery, 5 achieved major pathological remission (MPR)
.

4 The First Affiliated Hospital of Guangxi Medical University conducted a study to evaluate the prognosis of patients undergoing conversion hepatectomy after treatment with liver cancer with insufficient residual liver by portal vein ligation combined with apatinib and carrelizumab

In terms of efficacy biomarkers, a study explored the efficacy biomarkers of carrelizumab combined with apatinib for neoadjuvant treatment of locally advanced cholangiocarcinoma
.

6

In terms of other digestive system tumors, a phase Ib study of carrelizumab combined with apatinib neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma led by the Chinese Academy of Medical Sciences was included in the poster link.
After 29 cases of neoadjuvant treatment Among patients undergoing esophagectomy, 15 achieved MPR and 7 achieved pathological complete remission (pCR)
.

7 The team of Professor Liu Lian from Qilu Hospital of Shandong Province evaluated the application of carrelizumab combined with apatinib and S-1±oxaliplatin neoadjuvant therapy or conversion therapy in patients with locally advanced cT4a/bN+ gastric cancer.

Lung cancer: combination therapy, exploration of more advanced patients

In the field of lung cancer, a total of 1 poster and 2 online abstracts were selected for this ASCO conference
.

Including the research design of the Zhao Mingfang team of the First Affiliated Hospital of China Medical University on carrelizumab monotherapy or combined with apatinib for the treatment of PD-L1-positive advanced lung sarcomatoid carcinoma was selected for the poster of this conference, and we look forward to the announcement of follow-up research results
.
9 The team of Professor Liu Li and Meng Rui from the Union Hospital of Tongji Medical College of Huazhong University of Science and Technology on the treatment of advanced EGFR mutation non-small cell lung cancer after carrelizumab plus apatinib with or without body stereotactic radiotherapy Effectiveness studies have initially demonstrated the benefits of carrelizumab combined with apatinib± after radiotherapy in the treatment of EGFR-mutant NSCLC
.
10Professor Pan Yueyin from the First Affiliated Hospital of the University of Science and Technology of China included more patients with low PS scores and later disease stages, and evaluated carrelizumab combined with chemotherapy followed by sequential apatinib for second-line treatment of advanced EGFR-negative lungs Efficacy and safety in patients with adenocarcinoma
.
11

       Multi-tumor species, all blooming

       In other tumor treatment fields, Professor Zhong Laiping from the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine has carried out a study of carrelizumab combined with apatinib in the induction treatment of resectable locally advanced oral squamous cell carcinoma, preliminary results of the study It shows that carrelizumab combined with apatinib is well tolerated, and the MPR rate is higher than that of traditional induction chemotherapy
.
12 The team of Professor Guo Jun from Peking University Cancer Hospital announced the study of apatinib combined with carrelizumab in the treatment of advanced metastatic acral melanoma.
Among 27 patients with evaluable efficacy, the ORR rate was 22.
2%.
The DCR rate was 77.
8%, and the survival results are still under follow-up
.
13

       In addition, in terms of new drug combination therapy, the team of Professor Cheng Ying from Jilin Cancer Hospital has carried out a phase I study of IDO inhibitor (SHR9146) plus carrelizumab with or without apatinib in the treatment of advanced solid tumors.
, SHR9146 combined with Carrelizumab±apatinib has acceptable safety in patients with advanced solid tumors, and we look forward to further clinical research results
.
14

       In addition to the above-mentioned "Shuang Ai" related treatment research progress, Hengrui Medicine has been selected for this ASCO meeting with a total of more than 60 studies, involving the field of multi-tumor treatment, with fruitful results
.
The ASCO conference once again demonstrated to the world the strength of China's oncology clinical research and the rise of China's national pharmaceutical companies
.
The publication and update of a number of research results will promote the development of China's oncology field towards a higher and stronger goal, thereby benefiting more Chinese cancer patients
.

       The above research results are from the official website of the 2021ASCO annual meeting, as of May 26, 2021
.

       references:

       1.
Yun Zhang, Jianming Xu, Jie Shen, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4076).

       2.
Gang Liu, Liansheng Gong, Wenxuan Zhou, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16120)

       3.
Wenge Xing, Zhi Guo.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4160)

       4.
Yongxiang Xia, Ping Wang, Liyong Pu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4082)

       5.
Zhiming Zeng, Guangzhi Zhu, Huasheng Huang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16132)

       6.
Zhen Wang.
J Clin Oncol 39, 2021 (suppl 15; abstr 4047)

       7.
Song Li, Wenbin Yu, Fei Xie, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4061).

       8.
Jian-hua Rao, Chen Wu, Hui Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16126)

       9.
Mingfang Zhao, Tao Han.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9130)

       10.
Rui Meng, Lu Wu, Kai Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21128)

       11.
Yueyin Pan, Fengshou Jiang, Yingying Du,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21051)

       12.
Lai-Ping Zhong, Wu-tong Ju, Rong-hui Xia,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 6052)

       13.
Xuan Wang, Chuanliang Cui, Bin Lian,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 9539)

       14.
Ying Cheng, Ying Liu, Jinhua Xu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 3101)